Literature DB >> 8918567

The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines.

J al-Mughales1, T H Blyth, J A Hunter, P C Wilkinson.   

Abstract

The majority of synovial fluids from 29 rheumatoid arthritis patients were strongly attractive for normal blood lymphocytes judged by assays of polarization and collagen gel invasion. While rheumatoid synovial fluids contained IL-15, IL-8, monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory protein-1 alpha (MIP-1 alpha) at levels sufficient to attract lymphocytes, inhibition of the activity of any single cytokine using specific antibody did not abolish the activity of the fluid. However combinations of anti-cytokine antibodies used together (anti-IL-15+anti-MCP-1; anti-IL-8+anti-MCP-1 or +anti-MIP-1 alpha) inhibited most of the activity, suggesting that attraction of lymphocytes by the fluids is due to a combination of attractants. Blood lymphocytes required activation by overnight culture to respond optimally, while rheumatoid synovial tissue lymphocytes responded to synovial fluids without a requirement for a period of culture. Lymphocytes derived from rheumatoid synovial fluids were poorly responsive to locomotor stimulants. Most of the responding cells from blood mononuclear cell fractions were T lymphocytes of the CD45RO isotype. Incubation in the presence of cyclosporin A or corticosteroids inhibited the response of lymphocytes to the fluids, but the presence of non-steroidal anti-inflammatory drugs (NSAIDs) and other agents used in therapy of the patients from whom the fluids were taken had no inhibitory effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8918567      PMCID: PMC2200589          DOI: 10.1046/j.1365-2249.1996.d01-836.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

Review 1.  G protein betagamma subunits as targets for small molecule therapeutic development.

Authors:  Alan V Smrcka; David M Lehmann; Axel L Dessal
Journal:  Comb Chem High Throughput Screen       Date:  2008-06       Impact factor: 1.339

Review 2.  G protein βγ subunits: central mediators of G protein-coupled receptor signaling.

Authors:  A V Smrcka
Journal:  Cell Mol Life Sci       Date:  2008-07       Impact factor: 9.261

3.  Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis.

Authors:  T Matsui; T Akahoshi; R Namai; A Hashimoto; Y Kurihara; M Rana; A Nishimura; H Endo; H Kitasato; S Kawai; K Takagishi; H Kondo
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

4.  Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.

Authors:  Alan T Clucas; Ajit Shah; Yuanchao Derek Zhang; Vincent F Chow; Ronald P Gladue
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 5.  Chemokines in joint disease: the key to inflammation?

Authors:  J J Haringman; J Ludikhuize; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

6.  Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.

Authors:  J J Haringman; M C Kraan; T J M Smeets; K H Zwinderman; P P Tak
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

7.  Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12.

Authors:  Graeme O'Boyle; Paul Mellor; John A Kirby; Simi Ali
Journal:  FASEB J       Date:  2009-08-10       Impact factor: 5.191

8.  Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation.

Authors:  D M Lehmann; A M P B Seneviratne; A V Smrcka
Journal:  Mol Pharmacol       Date:  2007-11-15       Impact factor: 4.436

9.  Expression and function of aminopeptidase N/CD13 produced by fibroblast-like synoviocytes in rheumatoid arthritis: role of CD13 in chemotaxis of cytokine-activated T cells independent of enzymatic activity.

Authors:  Rachel Morgan; Judith Endres; Nilofar Behbahani-Nejad; Kristine Phillips; Jeffrey H Ruth; Sean C Friday; Gautam Edhayan; Thomas Lanigan; Andrew Urquhart; Kevin C Chung; David A Fox
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

10.  Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis.

Authors:  C Y Ho; C K Wong; E K Li; L S Tam; C W K Lam
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.